<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519281</url>
  </required_header>
  <id_info>
    <org_study_id>N-17-2020</org_study_id>
    <nct_id>NCT04519281</nct_id>
  </id_info>
  <brief_title>Role of Vitamin C in Cardiac Vasoplegia After Cardiopulmonary Bypass</brief_title>
  <official_title>Role of Preoperative IV Administration of Vitamin C in Patients at Risk for Cardiac Vasoplegia After Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel group double-blind, randomized-controlled trial with 1:1 randomization&#xD;
      ratio which will be conducted over a period of 6 months to study the effect of vitamin C&#xD;
      administration on the amount of noradrenaline given post-operatively to patients after CPB.&#xD;
      Two groups will be included; Group (A) patients undergoing open heart surgeries who will&#xD;
      receive IV ascorbic acid (treatment group) and Group (B) patients undergoing open heart&#xD;
      surgeries who will not receive ascorbic acid or will receive a placebo (control group). Each&#xD;
      patient will be subjected to assessments of the doses of noradrenaline given from the end of&#xD;
      surgery until weaning as well as hemodynamics in the first 2 hours and then at intervals of 6&#xD;
      hours up to 3 days following surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Rationale:&#xD;
&#xD;
      Cardiac vasoplegia is a known phenomenon after cardiopulmonary bypass (CPB) occurring in up&#xD;
      to 44% of patients. Severe forms of such condition refractory to vasopressors are associated&#xD;
      with poor outcomes. New agents e.g. ascorbic acid that can alter the systemic vascular&#xD;
      resistance in cardiac vasoplegia have been suggested as an attempt to avoid or at least&#xD;
      reduce the use of IV vasopressors and their induced systemic hypo-perfusion.&#xD;
&#xD;
      Objectives :&#xD;
&#xD;
        -  Primary objective: to study the effect of vitamin C administration on the amount of&#xD;
           noradrenaline given post-operatively to patients after CPB&#xD;
&#xD;
        -  Secondary objectives: to study the effect of vitamin C administration on the time to&#xD;
           weaning from noradrenaline&#xD;
&#xD;
      Study population &amp; Sample size :&#xD;
&#xD;
      Patients undergoing cardiac surgeries with CPB having risk factors for cardiac vasoplegia&#xD;
      like diabetes mellitus and chronic renal failure.&#xD;
&#xD;
      50 patients will be needed in each group (treatment and control)&#xD;
&#xD;
      Study Design :&#xD;
&#xD;
      A parallel group double-blind, randomized-controlled trial, with 1:1 randomization ratio 2&#xD;
      groups will be included;&#xD;
&#xD;
      -Group (A) patients undergoing open heart surgeries who will receive IV ascorbic acid. -Group&#xD;
      (B) patients undergoing open heart surgeries who will not receive ascorbic acid or will&#xD;
      receive a placebo (Control Group).&#xD;
&#xD;
      Methods :&#xD;
&#xD;
      Each patient will be subjected to the following assessments:&#xD;
&#xD;
      -Pre-operative patient characteristics: demographic data, co-morbidities, pre-operative echo&#xD;
      findings,… -Intra-operative details: procedures, time parameters,… the doses of noradrenaline&#xD;
      given from the end of surgery until weaning or death and hemodynamics in the first 2 hours&#xD;
      and then at intervals of 6 hours up to 3 days following surgery. -Postoperative data: echo&#xD;
      parameters, patient outcome, time of discharge,…&#xD;
&#xD;
      Outcome parameter (s):&#xD;
&#xD;
      -Primary outcome: the area under the dose-time curve of noradrenaline -Secondary outcome&#xD;
      measures: the duration of vasopressor (noradrenaline) infusion till weaning up to 3 days&#xD;
      following surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>amount of noradrenaline need</measure>
    <time_frame>3 days</time_frame>
    <description>to study the effect of vitamin C administration on the amount of noradrenaline given post-operatively to patients after CPB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of noradrenaline need</measure>
    <time_frame>3 days</time_frame>
    <description>to study the effect of vitamin C administration on the time to weaning from noradrenaline</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>to Study the Effect of Vitamin C Administration on the Amount and the Time of Weaning of Noradrenaline Given Post-operatively to Patients After CPB</condition>
  <arm_group>
    <arm_group_label>Group (A)</arm_group_label>
    <description>consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (B)</arm_group_label>
    <description>consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV of vitamin C</intervention_name>
    <description>administration of high-dose of IV vitamin C perioperatively</description>
    <arm_group_label>Group (A)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A parallel group double-blind, randomized-controlled trial, with 1:1 randomization ratio 2&#xD;
        groups will be included;&#xD;
&#xD;
          -  Group (A) consists of 50 patients undergoing open heart surgeries who will receive IV&#xD;
             ascorbic acid.&#xD;
&#xD;
          -  Group (B) consists of 50 patients undergoing open heart surgeries who will not receive&#xD;
             ascorbic acid or will receive a placebo (Control Group).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing cardiac surgeries with CPB having risk factors for cardiac&#xD;
             vasoplegia like diabetes mellitus and chronic renal failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo surgeries without cardiopulmonary bypass (off-pump)&#xD;
&#xD;
          -  Patients undergoing surgeries for congenital cardiac disease&#xD;
&#xD;
          -  Patients performing heart transplantation and combined cardiac surgeries&#xD;
&#xD;
          -  Patients with low pre-operative left ventricular ejection fraction (LVEF)&#xD;
&#xD;
          -  Patients refusing to participate&#xD;
&#xD;
          -  Patients who receive vasopressors other than noradrenaline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noha Asem, MD</last_name>
      <phone>00201003657120</phone>
      <email>kasralainirec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Soha Elmorsy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael Siory, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci. 2015 Jan;349(1):80-8. doi: 10.1097/MAJ.0000000000000341. Review.</citation>
    <PMID>25247756</PMID>
  </reference>
  <reference>
    <citation>Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 2010 Summer;22(2):140-4. doi: 10.1053/j.semtcvs.2010.09.007. Review.</citation>
    <PMID>21092891</PMID>
  </reference>
  <reference>
    <citation>Wieruszewski PM, Nei SD, Maltais S, Schaff HV, Wittwer ED. Vitamin C for Vasoplegia After Cardiopulmonary Bypass: A Case Series. A A Pract. 2018 Aug 15;11(4):96-99. doi: 10.1213/XAA.0000000000000752.</citation>
    <PMID>29634537</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hesham Mostafa Ahmed Alkady</investigator_full_name>
    <investigator_title>Prof. A. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical outcomes are to be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

